MedTrace Logo

Combination Chemotherapy in Treating Younger Patients With Hodgkin Lymphoma

NCT00666484 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2014-12-04

No results posted yet for this study

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. It is not yet known which regimen of combination chemotherapy is more effective for Hodgkin lymphoma.

PURPOSE: This phase II trial is studying the side effects of three different regimens of combination chemotherapy and to see how well they work in treating younger patients with Hodgkin lymphoma.

Conditions

Interventions

DRUG

cyclophosphamide

DRUG

doxorubicin hydrochloride

DRUG

etoposide

DRUG

prednisolone

DRUG

procarbazine hydrochloride

DRUG

vincristine sulfate

RADIATION

radiation therapy

Sponsors & Collaborators

  • University College, London

    lead OTHER

Principal Investigators

  • Kirit Ardeshna · University College London Hospitals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2012-09-30
Completion
2012-09-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00666484 on ClinicalTrials.gov